Login
Search
Search
0 Dates
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Real-world impact of sacubitril/valsartan on the quality of life of heart failure patients
Session:
Posters - D. Heart Failure
Speaker:
Marta Afonso Nogueira
Congress:
CPC 2021
Topic:
D. Heart Failure
Theme:
10. Chronic Heart Failure
Subtheme:
10.2 Chronic Heart Failure – Epidemiology, Prognosis, Outcome
Session Type:
Posters
FP Number:
---
Authors:
Marta Afonso Nogueira; Marta Afonso-Silva; Valeska Andreozzi; Björn Vandewalle; Fernanda Ferreira; Lurdes Mónica; Liliana Cruz; Madalena Guimarães; Gonçalo Proença
Abstract
<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Cambria"><strong><span style="font-family:Arial">Introduction: </span></strong><span style="font-family:Arial">Although in PARADIGM-HF trial sacubitril/valsartan has demonstrated to improve quality of life (QoL) versus enalapril, in heart failure with reduced ejection fraction (HFrEF), there is still limited evidence in real world settings.</span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Cambria"><strong><span style="font-family:Arial">Aim: </span></strong></span></span><span style="font-size:12pt"><span style="font-family:Cambria"><span style="font-family:Arial">Assess the impact of sacubitril/valsartan on the QoL of real world HFrEF patients.</span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Cambria"><strong><span style="font-family:Arial">Methods: </span></strong></span></span><span style="font-size:12pt"><span style="font-family:Cambria"><span style="font-family:Arial">Data from a prospective cohort of patients followed in a Portuguese HF clinic were analysed. </span><span style="font-family:Arial">QoL was assessed by the Kansas City Cardiomyopathy </span><span style="font-family:Arial">Questionnaire (KCCQ) administered at each medical visit. KCCQ scores in percentage range from 0 to 100, with higher scores meaning better QoL.</span></span></span><span style="font-size:12pt"><span style="font-family:Cambria"><span style="font-family:Arial"> Included patients had a diagnosis of HF, started sacubitril/valsartan between Nov/2017-Oct/2019 and had at least one KCCQ assessment at any time point during the first year of sacubitril/valsartan treatment.</span></span></span><span style="font-size:12pt"><span style="font-family:Cambria"><span style="font-family:Arial"> A linear mixed-effects model was used to estimate the mean KCCQ score and mean change from baseline at each visit. The proportion of patients with clinically meaningful improvements in KCCQ score, defined as an increment of at least five points, and stable patients, defined as either an increase or decrease below five points, were also computed.</span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Cambria"><strong><span style="font-family:Arial">Results:</span></strong> </span></span><span style="font-size:12pt"><span style="font-family:Cambria"><span style="font-family:Arial">Eighty patients met inclusion criteria and were analysed. The mean age of patients was 72.1 (standard deviation [SD]: 10.7) years and the majority were male (70.0%). Most patients had hypertension (66.2%), 47.5% had atrial fibrillation and 36.2% diabetes. The mean baseline left ventricular ejection fraction was 32.1% (SD:6.5) and 61.0% were New York Heart Association (NYHA) II patients. Over 12 months of follow-up, the mean estimated KCCQ score showed a trend towards improvement, from 70.1, at baseline, to 72.9 at 12 months. Mean change from baseline at 12 months was 2.4 (standard error: 4.6). Among patients with available data at 12 months, 44.4% showed a clinically meaningful improvement compared with baseline, while 33.3% had stable KCCQ scores. </span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Cambria"><strong><span style="font-family:Arial">Conclusions: </span></strong></span></span><span style="font-size:12pt"><span style="font-family:Cambria"><span style="font-family:Arial">Sacubitril/valsartan is suggested to generate considerable improvements in quality of life of HF patients in a real-world setting in Portugal. These results reinforce the positive trends already observed in previous studies. </span></span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site